您好,欢迎来到科研在线!科研采购 · 选型 · 实验方法
首页产品库品牌馆产品类别品牌新闻会议会展产品试用求职招聘资讯专题教程
PRO / Antibodies

Anti-Human CD22 (Epratuzumab Biosimilar)

Anti-Human CD22 (Epratuzumab Biosimilar)

英诺赛图(InnoCyto)的 Anti-Human CD22 (Epratuzumab Biosimilar)(克隆 Epratuzumab) 为人源 IgG1 抗体,靶向 CD22(别名 BL-CAM 等),适用于流式细胞术。提供 1 mg、5 mg、20 mg 规格,目录价 ¥1,695 起,仅供科研使用(RUO)。

生物试剂 供应商 上海英诺赛图 ↗ 型号 502601 更新 2026-11-12
参考价格区间
¥1,695
含税参考价,实际以配置与渠道报价为准
本条目供应商 上海英诺赛图原厂 1865个条目 进入企业主页

01产品图片

02产品简介

英诺赛图(InnoCyto)的 Anti-Human CD22 (Epratuzumab Biosimilar)(克隆 Epratuzumab) 为人源 IgG1 抗体,靶向 CD22(别名 BL-CAM 等),适用于流式细胞术。提供 1 mg、5 mg、20 mg 规格,目录价 ¥1,695 起,仅供科研使用(RUO)。

03产品介绍

规格与货号

502601 | 1 mg | ¥1,695

502602 | 5 mg | ¥4,407

502603 | 20 mg | ¥13,560

Product Details

Product Description|Epratuzumab Biosimilar, CD22 Monoclonal Antibody

Regulatory Status|RUO

Species specificity|Human

Storage Conditions|4ºC

Maximal Shelf Life|12 months

See All Formats|Clone Epratuzumab

Background Information

Epratuzumab is a humanized monoclonal antibody that belongs to the immunoglobulin G1 kappa (IgG1κ) subclass and is engineered to target CD22, a transmembrane glycoprotein expressed primarily on B lymphocytes. Structurally, Epratuzumab is a recombinant glycoprotein with a molecular mass of approximately 145 to 150 kilodaltons (kDa). The molecule is composed of two identical heavy chains and two identical light chains connected by interchain disulfide bonds, forming the characteristic Y-shaped antibody configuration typical of IgG immunoglobulins. Each heavy chain contains one variable (VH) domain and three constant regions (CH1-CH3), and each light chain comprises one variable (VL) and one constant (CL) domain. The antibody is produced in mammalian expression systems, such as Chinese Hamster Ovary (CHO) cells, ensuring proper glycosylation and folding necessary for biological stability and activity.

The antigen-binding regions of Epratuzumab, located within the complementarity-determining regions (CDRs) of the VH and VL domains, are derived from murine antibody sequences engineered into a human IgG framework to achieve specific recognition of CD22. This epitope binding occurs with high affinity through non-covalent interactions, including hydrogen bonding and van der Waals forces. CD22, a member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family, functions as an inhibitory coreceptor that modulates B-cell receptor (BCR) signaling. Upon binding to CD22, Epratuzumab influences intracellular signaling dynamics by promoting receptor internalization and partial modulation of downstream pathways involving calcium mobilization and phosphatase recruitment, such as SHP-1 activation in experimental systems.

The Fc (fragment crystallizable) region of Epratuzumab contributes to its stability and pharmacokinetic properties through interactions with neonatal Fc receptors (FcRn), which extend circulating half-life. As an IgG1 molecule, it can also interact with Fc gamma receptors (FcγRs), enabling potential effector functions like limited antibody-dependent cellular cytotoxicity (ADCC) under defined experimental conditions. Overall, Epratuzumab exemplifies a rationally engineered humanized antibody structure optimized for selective targeting of B-cell surface receptors and modulation of immune-signaling pathways in molecular and cellular studies.

Data Sheets

Cat # Size Price Quantity 5026011 mg Add to Cart5026025 mg Add to Cart50260320 mg Add to Cart

04完整参数表

参数由厂商资料整理,采购前请以最终报价单与技术协议为准。

包装规格1 mg
CloneEpratuzumab
ApplicationFlow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionEpratuzumab Biosimilar, CD22 Monoclonal Antibody
IsotypeHuman IgG1
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenHuman CD22
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Storage Conditions4ºC
SynonymsSiglec-2
RRIDAB_3739302
Target NameCD22, BL-CAM, Siglec-2
Antibody TypeRecombinant
目录价¥1,695

05荣誉与资质

该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。

  • 营业执照未上传
  • 品牌授权未上传
  • 产品检测报告未上传
会员身份
收费会员
经营身份
原厂
成立年份
2020 年
所在地
上海
收录条目
1865 个
平台核验
平台代管
向品牌方索取资质文件

06品牌与供应商

上海英诺赛图 原厂
InnoCyto

以可信赖的细胞研究试剂,助力科研突破

进入企业主页
1865 本目录条目
产地 / 总部上海市浦东新区
成立年份2020 年
本目录主营生化试剂 / 蛋白与抗体

InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。

售后与服务

品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。

引用此条目 产品目录 · 更新于 2026-11-12
科研在线(TeleVM). Anti-Human CD22 (Epratuzumab Biosimilar)(502601)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/anti-human-cd22-epratuzumab-biosimilar.html.
TeleVM. (2026, November 12). Anti-Human CD22 (Epratuzumab Biosimilar)(502601). 产品目录. https://www.suprotek.cn/products/item/anti-human-cd22-epratuzumab-biosimilar.html
@misc{biocsp_item_anti_human_cd22_epratuzumab_biosimilar,
  title        = {Anti-Human CD22 (Epratuzumab Biosimilar)(502601)},
  author       = {{科研在线}},
  year         = {2026},
  howpublished = {产品目录},
  note         = {更新于 2026-11-12,产品目录},
  url          = {https://www.suprotek.cn/products/item/anti-human-cd22-epratuzumab-biosimilar.html}
}

GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。

许可:CC BY-NC 4.0 · 转载注明来源
获取正式报价

Anti-Human CD22 (Epratuzumab Biosimilar)

提交后由平台转给品牌方,通常 1 个工作日内联系。不需要注册。